Abstract 223P
Background
Given the multiple treatment choices for advanced renal cell carcinoma (RCC), it is important to understand the treatment preferences of patients and physicians for the treatment of advanced RCC. This study aimed to understand patients’ and physicians’ preferences that influence their treatment choices for advanced RCC.
Methods
Qualitative interviews were conducted for 16 physicians and 10 advanced RCC patients in South Korea, Australia, Hong Kong and Taiwan. Physicians and patients each ranked 36 attributes related to treatment efficacy, side effects and mode of administration (score, 1-10) in terms of their preference for the treatment of advanced RCC. The scores of the top 10 attributes were aggregated among physicians and among patients to derive the overall score.
Results
For attributes related to treatment efficacy, physicians ranked years of survival (score =78), progression-free survival (score =78) and overall survival at 1 year (score =71) as most important, while patients ranked progression-free survival (score =54), years of survival (score =45), and duration of response (score =39) as most important. For attributes related to treatment side effects, physicians ranked grade 3 or 4 pneumonitis (score =40), chance of admission due to treatment side effects (score =37) and grade 3 or 4 gastrointestinal perforation (score = 33) as most important, while patients ranked grade 3 or 4 chronic kidney disease (score = 20), grade 3 or 4 myelosuppression (score =19) and chance of admission due to treatment side effects (score =17) as most important. The attributes prioritized by physicians did not differ by favourable vs intermediate/poor risk patient groups. Physicians and patients did not rank attributes related to mode of administration within the top 10.
Conclusions
Physicians and patients have slightly different preferences while making treatment choices. This study demonstrates that physicians and patients prioritized attributes related to treatment efficacy compared to side effects. A more effective dialogue between HCP and patient is needed to help decision-making in selecting the most appropriate treatment for advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA Solutions Asia Pte. Ltd.
Funding
MSD International GmbH, Singapore Branch.
Disclosure
N. Oliveira, B.C.W. Li, M. Kim, I. Park, Y. Su, C.K. Yang, A. Zhang, K.C.W. Wong: Financial Interests, Personal, Advisory Board: MSD. A. Dsouza: Financial Interests, Personal, Full or part-time Employment: MSD Singapore. S. Chua, E.M. Tan: Financial Interests, Personal, Full or part-time Employment, Commissioned to carry out this study (IQVIA): IQVIA Asia Pacific, Singapore. C. Spiteri: Financial Interests, Personal, Full or part-time Employment: MSD Australia.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract